Category: InVivo Therapeutics Corp.Syndicate content

InVivo adds 3rd site to clinical trial

March 26, 2015 by Mark Hollmer

InVivo Therapeutics adds a 3rd clinical site to a feasibility study of its biodegradable implant to treat acute spinal cord injuries.

InVivo adds 3rd site to clinical trial

InVivo Therapeutics readies reverse split ahead of NASDAQ listing

March 24, 2015 by Brad Perriello

InVivo Therapeutics readies a 1-for-4 reverse stock split ahead of a planned listing on the NASDAQ stock exchange.

InVivo Therapeutics readies reverse split ahead of NASDAQ listing

RIP former Evalve CEO Powell | Personnel Moves

March 23, 2015 by Brad Perriello

Ferolyn Powell, the former CEO of Evalve who led it to a $410 million acquisition by Abbott, is killed in a motorbike accident in Thailand.

RIP former Evalve CEO Powell | Personnel Moves

Former Evalve CEO Ferolyn Powell, who led the MitraClip developer to a $410 million acquisition by Abbott (NYSE:ABT), died this month in a motorbike accident in northern Thailand, her family said yesterday.

InVivo Therapeutics reports narrowed 2014 losses

March 16, 2015 by Val Kennedy

InVivo Therapeutics reports narrowed annual losses, due in part to changes in the market value of the company's derivative warrant liability.

InVivo Therapeutics reports narrowed losses

(OTC:IVOB) reported a narrowed annual loss, due in part to changes in the market value of the company's derivative warrant liability.

InVivo Therapeutics looks to raise $12m for spine trial

February 2, 2015 by Mark Hollmer

Massachusetts-based InVivo Therapeutics looks to raise $12 million in a direct offering as it enrolls the 2nd patient in a feasibility trial for its neuro-spinal scaffold.

InVivo Therapeutics looks to raise $12 for spine trial

InVivo cleared to advance spinal injury study

January 14, 2015 by Val Kennedy

InVivo Therapeutics gets a green light to reopen enrollment in a clinical study of its neuro-spinal scaffold for treating acute spinal cord injuries.

InVivo cleared to advance spinal injury study

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA OKs expedited enrollment for InVivo study

December 18, 2014 by Val Kennedy

The FDA approves an expedited enrollment plan for a 5-patient pivotal study testing InVivo Therapeutics' neuro-spinal scaffold devices in the treatment of severe spinal cord injuries.

FDA OKs expedited enrollment for InVivo study

Get the complete picture with a MassDevice Plus membership. Registered users can login here.